Salvat
Focus: Salvat is a small-molecule biotech focused on ophthalmology and immunology, headquartered in Miami with 201–500 employees. The company is heavily dependent on its lead product OTOVEL, which generated $4K in Part D spending.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Employees
201-500
Open Jobs
16+26 this month
Hot — 28 jobs added in 30d
Net +26 (28 new, 2 removed). Aggressive expansion phase.
Should You Work at Salvat?
AI assessmentSalvat offers pipeline depth and visa accessibility but carries material restructuring risk due to single-product dependency and unclear late-stage probability of success.
Why Work Here
- Strong Phase 3 pipeline with 10 programs in late-stage development, offering meaningful advancement opportunities in ophthalmology and adjacent fields
- Miami headquarters provides geographic diversity and potential cost-of-living advantage versus coastal biotech hubs
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
1 in 5yr
OTOVEL
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$4K (Part D)Stable
Peak3.6yr
Sole revenue driver; patent expires March 2030, creating urgent need for pipeline transition.
Help build intelligence for Salvat
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.